What do systematic reviews say?

492 questions · 535 findings · 56 reviews · Hypertension

Sort:Best matchNewestHighest certainty Download CSV

No studies found 37 · 6.9%GRADE not reported 34 · 6.4%Very low 91 · 17%Low 161 · 30.1%Moderate 136 · 25.4%High 76 · 14.2%

Intervention not reported

Triglycerides fluvastatin 20 mg/day · participants with normal or abnormal lipid profiles

1 finding from 1 review

Fluvastatin for lowering lipids 2018 · Cochrane Headline outcomes only
no estimate extracted
39 studies · 7510 participants
High

Intervention not reported

Triglycerides fluvastatin 40 mg/day · participants with normal or abnormal lipid profiles

1 finding from 1 review

Fluvastatin for lowering lipids 2018 · Cochrane Headline outcomes only
no estimate extracted
48 studies · 2646 participants
High

Intervention not reported

Triglycerides fluvastatin 80 mg/day · participants with normal or abnormal lipid profiles

1 finding from 1 review

Fluvastatin for lowering lipids 2018 · Cochrane Headline outcomes only
no estimate extracted
23 studies · 3623 participants
High

Intervention not reported

CI: Confidence interval · participants with normal or abnormal lipid profiles

The review found no eligible studies for this question.

1 finding from 1 review

Fluvastatin for lowering lipids 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Mean baseline values. · participants with normal or abnormal lipid profiles

1 finding from 1 review

Fluvastatin for lowering lipids 2018 · Cochrane Headline outcomes only
no estimate extracted
1 participants
GRADE not reported

Intervention not reported

WDAEs within 3‐12 weeks · participants with normal or abnormal lipid profiles

It is very uncertain whether the intervention changes WDAEs within 3‐12 weeks (very low certainty).

1 finding from 1 review

Fluvastatin for lowering lipids 2018 · Cochrane Headline outcomes only
RR 1.52 [0.94, 2.45]
16 studies · 3023 participants
Very low

Intervention not reported

LDL‐cholesterol fluvastatin 20 mg/day · participants with normal or abnormal lipid profiles

1 finding from 1 review

Fluvastatin for lowering lipids 2018 · Cochrane Headline outcomes only
no estimate extracted
55 studies · 9010 participants
High

Intervention not reported

LDL‐cholesterol fluvastatin 40 mg/day · participants with normal or abnormal lipid profiles

1 finding from 1 review

Fluvastatin for lowering lipids 2018 · Cochrane Headline outcomes only
no estimate extracted
57 studies · 3658 participants
High

Intervention not reported

LDL‐cholesterol fluvastatin 80 mg/day · participants with normal or abnormal lipid profiles

1 finding from 1 review

Fluvastatin for lowering lipids 2018 · Cochrane Headline outcomes only
no estimate extracted
32 studies · 4928 participants
High

Intervention not reported

CI: Confidence interval · participants with normal or abnormal lipid profiles

The review found no eligible studies for this question.

1 finding from 1 review

Fluvastatin for lowering lipids 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Mean baseline values. · participants with normal or abnormal lipid profiles

1 finding from 1 review

Fluvastatin for lowering lipids 2018 · Cochrane Headline outcomes only
no estimate extracted
1 participants
GRADE not reported

Intervention not reported

Total cholesterol fluvastatin 10 mg/day · participants with normal or abnormal lipid profiles

1 finding from 1 review

Fluvastatin for lowering lipids 2018 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 287 participants
High

Intervention not reported

Total cholesterol fluvastatin 20 mg/day · participants with normal or abnormal lipid profiles

1 finding from 1 review

Fluvastatin for lowering lipids 2018 · Cochrane Headline outcomes only
no estimate extracted
50 studies · 6309 participants
High

Intervention not reported

Total cholesterol fluvastatin 40 mg/day · participants with normal or abnormal lipid profiles

1 finding from 1 review

Fluvastatin for lowering lipids 2018 · Cochrane Headline outcomes only
no estimate extracted
55 studies · 2966 participants
High

Beta‐blockers vs placebo

Total mortality

Beta‐blockers showed no clear difference in total mortality compared with placebo (moderate certainty).

1 finding from 1 review

Beta‐blockers for hypertension 2017 · Cochrane Headline outcomes only
RR 0.99 [0.88, 1.11]
4 studies · 23613 participants
Moderate

Beta‐blockers vs diuretics

Withdrawals due to adverse events

Beta‐blockers showed no clear difference in withdrawal due to adverse effect compared with diuretics (low certainty).

1 finding from 1 review

Beta‐blockers for hypertension 2017 · Cochrane Headline outcomes only
RR 1.69 [0.95, 3]
3 studies · 11566 participants
Low

Beta‐blockers vs calcium channel blockers

Total mortality

Beta‐blockers showed no clear difference in total mortality compared with calcium‐channel blockers (moderate certainty).

1 finding from 1 review

Beta‐blockers for hypertension 2017 · Cochrane Headline outcomes only
RR 1.07 [1, 1.14]
4 studies · 44825 participants
Moderate

Beta‐blockers vs calcium channel blockers

Total cardiovascular disease

Beta‐blockers probably leads to higher total cardiovascular disease compared with calcium‐channel blockers (moderate certainty).

1 finding from 1 review

Beta‐blockers for hypertension 2017 · Cochrane Headline outcomes only
RR 1.18 [1.08, 1.29]
2 studies · 19915 participants
Moderate

Beta‐blockers vs calcium channel blockers

Stroke

Beta‐blockers probably leads to higher total stroke compared with calcium‐channel blockers (moderate certainty).

1 finding from 1 review

Beta‐blockers for hypertension 2017 · Cochrane Headline outcomes only
RR 1.24 [1.11, 1.4]
3 studies · 44167 participants
Moderate

Beta‐blockers vs calcium channel blockers

Total coronary heart disease

Beta‐blockers showed no clear difference in total coronary heart disease compared with calcium‐channel blockers (moderate certainty).

1 finding from 1 review

Beta‐blockers for hypertension 2017 · Cochrane Headline outcomes only
RR 1.05 [0.96, 1.15]
3 studies · 44167 participants
Moderate